Skip to main content
Equibles
PCSA logo

PCSA · Processa Pharmaceuticals, Inc. · Debt

Track PCSA — free

Use PCSA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PCSA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.95 -0.04 (-2.01%)
Rebalance outlook locked
Going-concern doubt — cleared Aug 14, 2026

The latest filing states the doubt was alleviated.

“Following our acquisition of Vidya and closing of the related $200 million gross private placement (from which we received net proceeds of $183.3 million) on July 30, 2026, we believe our cash and cash equivalents will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$5.56M
Shares
2.79M

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.
Key facts CIK 1533743 CUSIP 74275C403 13F (30d) 12 filings 12 filers Visit website Investor relations